MR
Marker Therapeutics, Inc.
MRKR · NASDAQ
$1.18 -0.84% (-$0.01)
1M -15.11%
Market Cap $19.7M
P/E Ratio -
Div. Yield -
ROE 56.96%
Bulios Fair Price
$1.4
18.6% upside
Current Price
$1.18
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MRKR is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
49 /100
Fair P/B 1.62x
P/S 15.96x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 5.02%
FCF growth N/A
EPS growth N/A
Profitability
0 /100
Weak Op. margin 868.95%
Gross margin 320.83%
FCF margin 791.32%
Quality
1 /100
Poor ROA 59.70%
ROIC 87.91%
Asset turnover 0.08x
Debt
100 /100
Low Current ratio 6.03x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
39 /100
Moderate EPS volatility 6.30%
Beta 1.53x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MRKR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Juan F. Vera
Employees
5
Headquarters
Houston
Upcoming events
12 NOV
Earnings
Upcoming earnings report